PDT has been a well-studied therapy for the treatment of cancer since it was invented more than 100 years ago18. Over the last decade, PDT has been applied as an antimicrobial strategy and has shown effectiveness against some antibiotic-resistant pathogenic bacteria12. Compared to the planktonic state, bacterial biofilms appear to be more resistant to antibiotic treatment3, while the effect of ALA-PDT on biofilms has not been fully investigated yet.
In this article, an in vitro ALA-PDT system was described, and the antibacterial effect of this model on S. aureus biofilms was demonstrated. Two methods were used to test the effect of ALA-PDT on S. aureus biofilms in this protocol. While the CFU test demonstrated the antimicrobial effect by calculating the viable cells after treatment, fluorescent viability staining with CLSM not only confirmed the results of the CFU test but also detected the morphological character of the live and dead bacteria in situ. Using both analytical techniques together is an ideal approach for determining the effect of ALA-PDT on biofilms. Based on the CLSM results, the dead bacterial cells were predominantly distributed in the upper layer, while some of the bacteria in the bottom layer remained alive15. The latter may be the source of bacterial colonies in the CFU assay. A similar result has been observed in a study conducted by O'Neill et al., which was explained by the low accumulation of photosensitizers in the inner layer or the inability of the light to penetrate these regions19.
In this protocol, the mature biofilm was incubated with 10 mM of ALA for 1 h before exposure to PDT. These parameters were chosen based on the results of two pre-experiments. First, the antimicrobial effect of ALA was tested against biofilms without light irradiation using different concentrations of ALA and different amounts of time for incubation with S. aureus biofilms. The groups without any bactericidal effect were chosen as the candidates. Second, the PDT effect was detected in these candidate groups, and the group with the most potent bactericidal effect was finally chosen in this protocol. Thus, the parameters used in this protocol ensured that there was no bactericidal effect of ALA alone. A 1-h incubation time is significantly shorter than those used in previous studies17,20, making it convenient for in vitro studies and for potential application in future clinical treatments.
There are several critical points for successful use of this model. First, the whole process involving the manipulation of ALA treated bacteria should be performed in darkness. Second, the manipulation of the mature biofilms should be gentle to avoid disturbing the formed biofilm. Third, in the CFU test, scraping the bacteria from the bottom of the plates should be thorough. Finally, the freshly prepared ALA should be used; therefore, it is better to prepare ALA right before the experiment.
Although this protocol can be used to test the effect of ALA-PDT on S. aureus biofilms in vitro, it is still different from the clinical situation in vivo. For example, biofilms in the human body are usually formed by multiple bacterial strains21,22, and the environment in vivo is more complex than that in vitro, which might influence the effect of PDT. Therefore, future in vivo experiments are needed for a full evaluation of the antibacterial effects of ALA-PDT on S. aureus biofilms. However, because of its advantages of convenience and the ethical issues of conducting in vivo studies, this in vitro platform will be useful and practical to improve the study of the effects of ALA-PDT on S. aureus biofilms. It should also be noted that although ALA, a precursor of the photosensitizer PpIX, has favorable characteristics, including rapid clearance, less and shorter-lasting cutaneous photosensitivity, limited light penetration restricted to superficial lesions and especially its non-cumulative toxicity14, the light dose and photosensitizer concentration required to achieve bacteria killing may still have a bystander effect on host cell viability. Thus, studying the modification of ALA23 for targeted therapy of selected pathogenic bacterial strains like S. aureus is valuable for future antimicrobial therapy.
This protocol can not only be used for the study of the effect of ALA-PDT on S. aureus strains in the future but can also be referenced to study its effect on biofilms formed by other bacteria. The parameters, such as the concentration of ALA and the duration of the bacteria incubation with ALA, may vary among different bacterial strains, but the principles discussed above are commonly shared.